StockNews.com Begins Coverage on TRACON Pharmaceuticals (NASDAQ:TCON)

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.

TRACON Pharmaceuticals Stock Performance

TCON stock opened at $0.07 on Tuesday. The firm has a market cap of $252,340.00, a P/E ratio of 0.11 and a beta of 1.35. The firm’s fifty day moving average is $0.36 and its 200 day moving average is $2.25. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.